Document:

EX-4.1

 Exhibit 4.1 
  

			
	

	  	CLIFFORD CHANCE LLP

 Dated as of December 13, 2019 

QUOTIENT LIMITED 
 and 

THE HOLDERS OF ORDINARY SHARES 

THAT ARE PARTY TO THIS AGREEMENT 
  

 
 REGISTRATION
RIGHTS AGREEMENT 
  
  

 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 ARTICLE I REGISTRATION
	  	 	2	 
			
	 Section 1.1
	  	Shelf Registration Statement	  	 	2	 
			
	 Section 1.2
	  	Registration Procedures	  	 	3	 
			
	 Section 1.3
	  	Registration Expenses	  	 	5	 
			
	 Section 1.4
	  	Miscellaneous	  	 	5	 
			
	 Section 1.5
	  	Registration Indemnification	  	 	5	 
		
	 ARTICLE II DEFINITIONS
	  	 	6	 
			
	 Section 2.1
	  	Defined Terms	  	 	6	 
			
	 Section 2.2
	  	Interpretation	  	 	8	 
		
	 ARTICLE III MISCELLANEOUS
	  	 	8	 
			
	 Section 3.1
	  	Term	  	 	8	 
			
	 Section 3.2
	  	Notices	  	 	9	 
			
	 Section 3.3
	  	Successors and Assigns	  	 	9	 
			
	 Section 3.4
	  	Governing Law	  	 	9	 
			
	 Section 3.5
	  	Counterparts	  	 	10	 
			
	 Section 3.6
	  	Entire Agreement	  	 	10	 
			
	 Section 3.7
	  	Amendment and Waiver	  	 	10	 
			
	 Section 3.8
	  	Invalid Provisions	  	 	10	 
			
	 Section 3.9
	  	No Third-Party Beneficiaries	  	 	11	 

  
 - i - 

 REGISTRATION RIGHTS AGREEMENT, dated as of December 13, 2019 (this
“Agreement”), among QUOTIENT LIMITED, a limited liability no par value company incorporated under the laws of Jersey, Channel Islands (the “Company”), CHRISTOPHER J. LINDOP
(“Mr. Lindop”), HEINO VON PRONDZYNSKI (“Mr. von Prondzynski”) and FRANZ WALT (“Mr. Walt”). 

W I T N E S S E T H: 

WHEREAS, Mr. Lindop, Mr. von Prondzynski and Mr. Walt previously purchased certain Ordinary Shares from the Company in
transactions not involving any public offering; 
 WHEREAS, in order to permit the public offer and resale from time to time of such
Ordinary Shares by Mr. Lindop, Mr. von Prondzynski and Mr. Walt, the Company has determined to grant registration rights to such Persons, on the terms and subject to the conditions set forth herein; and 

WHEREAS, in order to permit the Company to prepare and file the Shelf Registration Statement described herein, each of Mr. Lindop,
Mr. von Prondzynski and Mr. Walt has duly completed and delivered to the Company on or prior to the date hereof the selling shareholder questionnaire, the form of which is set forth in Exhibit B (the “Questionnaire”). 

NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements contained in this Agreement, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows: 

ARTICLE I 
 REGISTRATION

 Section 1.1 Shelf Registration Statement. 

(a) On the date hereof, the Company shall file with the Commission a registration statement on Form
S-3 providing for an offering to be made on a continuous basis pursuant to Rule 415 under the Securities Act (the “Shelf Registration Statement”), registering all Registrable Shares then held
by the Holders and including a plan and method of distribution, substantially in the form of Exhibit A hereto. 
 (b) Subject to
Section 1.1(c), the Company will use its reasonable best efforts to cause the Shelf Registration Statement to be declared effective by the Commission as soon as reasonably practicable and to keep the Shelf Registration Statement continuously
effective until the earlier of (i) the date on which all Registrable Shares covered by the Shelf Registration Statement have been sold thereunder in accordance with the plan and method of distribution disclosed in the prospectus included in the
Shelf Registration Statement or otherwise cease to be Registrable Shares; and (ii) the date on which this Agreement terminates pursuant to Section 3.1. 

 (c) Notwithstanding anything to the contrary contained in this Agreement, the Company shall
be entitled, from time to time, by providing written notice to the Holders whose Registrable Shares are registered under the Shelf Registration Statement, to require such Holders to suspend the use of the prospectus for the sales of Registrable
Shares under the Shelf Registration Statement during any Blackout Period. In the event of a Blackout Period, the Company shall notify in writing such Holders that, in the good faith judgment of the Company, the conditions described in the definition
of Blackout Period are met. After the expiration of any Blackout Period and without any further request from a Holder of Registrable Shares, the Company to the extent necessary shall as promptly as reasonably practicable prepare a post-effective
amendment or supplement to the Shelf Registration Statement or the prospectus, or any document incorporated therein by reference, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Shares included
therein, the prospectus will not include an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(d) Notwithstanding anything herein to the contrary, in no event shall Registrable Shares be offered and sold pursuant to the Shelf
Registration Statement and prospectus relating thereto pursuant to an underwritten offering without the prior written consent of the Company. 

Section 1.2 Registration Procedures. 

(a) In connection with the Shelf Registration Statement, the Company shall, as expeditiously as reasonably practicable (to the extent the
Company has not yet taken such action), subject to the provisions of Section 1.1: 
 (i) prepare and file with the Commission such
registration statement to effect registration in accordance with the intended plan and method of distribution, substantially in the form of Exhibit A hereto, and thereafter use reasonable best efforts to cause such registration statement to become
and remain effective pursuant to the terms of this Article I; 
 (ii) prepare and file with the Commission such amendments and supplements
to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective pursuant to the terms of this Article I, and comply with the provisions of the Securities Act with
respect to the disposition of all securities covered by such registration statement; 
 (iii) furnish to the Holders such number of
conformed copies of such registration statement and of each amendment and supplement thereto, such number of copies of the prospectus contained in such registration statement (including each preliminary prospectus and any summary prospectus) and
each free writing prospectus (as defined in Rule 405 of the Securities Act) (a “Free Writing Prospectus”) utilized in connection therewith and any other prospectus filed under Rule 424 under the Securities Act, in conformity with
the requirements of the Securities Act, and such other documents as such Holders may reasonably request in order to facilitate the public sale or other disposition of the Registrable Shares owned by such Holders; 

(iv) use reasonable best efforts to cause such Registrable Shares to be listed on the Nasdaq Global Market or such other securities exchange
on which the Ordinary Shares are then listed; 

  
 - 3 - 

 (v) as promptly as reasonably practicable notify in writing the Holders of the following
events: (A) the filing of such registration statement, any amendment thereto, the prospectus or any prospectus supplement related thereto or post-effective amendment to such registration statement or any Free Writing Prospectus utilized in
connection therewith, and, with respect to such registration statement or any post-effective amendment thereto, when the same has become effective; (B) any request by the Commission or any other Governmental Authority for amendments or
supplements to such registration statement or the prospectus or for additional information; (C) the issuance by the Commission of any stop order suspending the effectiveness of such registration statement or the initiation of any proceedings by
any Person for that purpose; and (D) subject to the provisions of this Agreement relating to a Blackout Period, upon the happening of any event that makes any statement made in such registration statement or related prospectus or any document
incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in such registration statement, prospectus or documents so that, in the case of such registration statement, it
will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the prospectus, it will not contain any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, and, at the request of any Holder, promptly as
reasonably practicable prepare and furnish to such Holder a reasonable number of copies of a supplement to or an amendment of such registration statement or prospectus as may be necessary so that, as thereafter delivered to the purchasers of such
Registrable Shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading; and 
 (vi) use reasonable best efforts to obtain the withdrawal of any order suspending the effectiveness of
such registration statement. 
 (b) Subject to Section 1.4(a), the Company may require each Holder to furnish the Company in writing
such information regarding each Holder and the distribution of Registrable Shares as the Company may from time to time reasonably request in writing to complete or amend the information required by the Shelf Registration Statement. 

(c) Each Holder agrees that (i) upon receipt of any notice from the Company of the happening of any event of the kind described in
clauses (B), (C) or (D) of Section 1.2(a)(v), such Holder shall forthwith discontinue such Holder’s disposition of Registrable Shares pursuant to the Shelf Registration Statement and prospectus relating thereto until such
Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 1.2(a)(v), or until it is advised in writing by the Company that the use of the applicable prospectus may be resumed, and has received copies
of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such prospectus and (ii) upon receipt of any notice from the Company of termination of this Agreement pursuant to clauses (a) or
(b) of Section 3.1, such Holder shall, as of the effective date of such termination, discontinue such Holder’s disposition of Registrable Shares pursuant to the Shelf Registration Statement and prospectus relating thereto. 

(d) Each Holder agrees that it will notify the Company, in writing, once all of its Registrable Shares have been sold, regardless of whether
the sale was pursuant to an effective registration statement under the Securities Act, pursuant to Rule 144 under the Securities Act or otherwise. 

  
 - 4 - 

 (e) Each Holder agrees that it will not make any offer relating to the Registrable Shares
that would constitute an “issuer free writing prospectus,” as defined in Rule 433 under the Securities Act, or that would otherwise constitute a Free Writing Prospectus, required to be filed with the Commission. 

Section 1.3 Registration Expenses. The Company shall bear all expenses incurred in connection with the performance of its
obligations under this Agreement; provided, however, that the Company shall have no obligation to pay for (i) any commissions or transfer taxes of any selling Holder, or (ii) the fees, disbursements and expenses of any
counsel to any Holder. 
 Section 1.4 Miscellaneous. 

(a) In addition to the Questionnaire, each Holder shall promptly provide the Company with such other information regarding such Holder that
the Company may reasonably request in connection with the Shelf Registration Statement to be filed by the Company for the benefit of the Holders pursuant to this Agreement. 

(b) Each Holder acknowledges and agrees that, notwithstanding the filing or effectiveness of the Shelf Registration Statement, dispositions of
Registrable Shares will be subject to the terms of its lock-up agreement with Jefferies LLC and Cowen and Company, LLC, dated November 4, 2019. 

Section 1.5 Registration Indemnification. 

(a) Each Holder shall, severally and not jointly, indemnify the Company, its directors, officers, shareholders, employees, accountants,
attorneys and agents and each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) the Company, from and against all losses, claims, damages, liabilities, costs, expenses
(including reasonable expenses of investigation and reasonable attorneys’ fees and expenses), judgments, fines, penalties, charges and amounts paid in settlement (collectively, the “Losses”), as incurred, arising out of, caused
by, resulting from or relating to any untrue statement (or alleged untrue statement) of material fact contained in the Shelf Registration Statement, prospectus, preliminary prospectus or Free Writing Prospectus or any amendment or supplement thereto
or any omission (or alleged omission) of a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, preliminary prospectus, Free Writing Prospectus or any amendment or supplement thereto,
in light of the circumstances under which they were made) not misleading, in each case solely to the extent, but only to the extent, that such untrue statement or omission is made in such registration statement, prospectus or preliminary prospectus
or Free Writing Prospectus or any amendment or supplement thereto in reliance upon and in conformity with written information regarding such Holder furnished to the Company by or on behalf of such Holder expressly for inclusion in such registration
statement, prospectus or preliminary prospectus or Free Writing Prospectus or any amendment or supplement thereto. 

  
 - 5 - 

 (b) If recovery is not available under the foregoing indemnification provisions for any
reason or reasons other than as specified therein, any Person who would otherwise be entitled to indemnification by the terms thereof shall nevertheless be entitled to contribution with respect to any Losses with respect to which such Person would
be entitled to such indemnification but for such reason or reasons, in such proportion as is appropriate to reflect the relative fault of the indemnifying party, on the one hand, and such indemnified party, on the other hand, in connection with the
actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party, the Person’s relative
knowledge and access to information concerning the matter with respect to which the claim was asserted, the opportunity to correct and prevent any such statement or omission, and other equitable considerations appropriate under the circumstances. It
is hereby agreed that it would not necessarily be equitable if the amount of such contribution were determined by pro rata or per capita allocation. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any Person who was not found guilty of such fraudulent misrepresentation. 
 (c) The
indemnification and contribution provided for under this Agreement shall survive the sale of the Registrable Shares and the termination of this Agreement. 

ARTICLE II 
 DEFINITIONS

 Section 2.1 Defined Terms. Capitalized terms when used in this Agreement shall have the following meanings: 

“Blackout Period” shall mean, in the event that the Board of Directors, the chief executive officer, the executive chairman or
the chief financial officer of the Company determines in good faith that the registration or sale of Registrable Shares would reasonably be expected to materially adversely affect or materially interfere with any bona fide material
financing of the Company or any material transaction under consideration by the Company or would require disclosure of information that has not been, and is not otherwise required to be, disclosed to the public, the premature disclosure of which
would materially adversely affect the Company, a period of up to sixty (60) days; provided that a Blackout Period may not occur more than two (2) times in any period of twelve (12) consecutive months or last,
together with any other Blackout Period, in the aggregate, for more than sixty (60) days in a 180 day period. 
 “Business
Day” shall mean any day other than a Saturday, Sunday or any other day on which banks located in New York, New York or Jersey, Channel Islands are authorized or required by Law to remain closed for the conduct of regular banking business.

 “Commission” shall mean the U.S. Securities and Exchange Commission or any other federal agency administering the
Securities Act. 

  
 - 6 - 

 “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. 
 “Form S-3” shall
mean a Form S-3 registration statement under the Securities Act or any successor form thereto. 

“Governmental Authority” shall mean any international, supranational, national, provincial, regional, federal, state, county,
municipal or local government, any instrumentality, subdivision, court, tribunal, panel, department, administrative hearing department, administrative or regulatory agency or commission or other authority thereof, or any quasi-governmental, or
applicable exchange, self-regulatory organization, including the Financial Industry Regulatory Authority, Inc. (FINRA), or any private body exercising any administrative, executive, judicial, legislative, policy, regulatory, taxing, importing or
other governmental or quasi-governmental authority or power of any nature, in each case whether U.S. or foreign. 

“Holder” shall mean each holder of Registrable Shares that is a Party to this Agreement. 

“Law” shall mean any federal, state, local, foreign or international law (including common law), code, treaty, bulletin,
administrative or judicial doctrine, statute, regulation, ordinance, rule, judgment, order, decree, award, approval, concession, grant, franchise, directive, guideline, policy, requirement, permit or other governmental restriction or any similar
form of decision or approval of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority. 

“Lindop Shares” shall mean the 50,000 Ordinary Shares owned by Mr. Lindop as of the date hereof and originally
subscribed for by Mr. Lindop pursuant to that certain Subscription Agreement, dated as of February 9, 2017, between the Company and Mr. Lindop, at a price of $6.41 per share (which was equal to the closing sales price of the
Company’s Ordinary Shares as reported on the Nasdaq Global Market on February 9, 2017), for aggregate proceeds of $320,500. 

“Ordinary Shares” shall mean ordinary shares of the Company of no par value per share. 

“Party” shall mean any party to this Agreement. 

“Person” shall mean any natural person, corporation, general partnership, limited partnership, limited or unlimited liability
company, proprietorship, association, trust, joint venture, joint stock company, unincorporated organization, other business entity or Governmental Authority. 

“Registrable Shares” shall mean (a) (i) in the case of Mr. Lindop, the Lindop Shares; (ii) in the case of
Mr. von Prondzynski, the Von Prondzynski Shares; and (iii) in the case of Mr. Walt, the Walt Shares; and (b) any Ordinary Shares received in respect of the securities referred to in clause (a), in connection with any share split
or subdivision, share dividend, distribution, recapitalization or similar transaction; provided that any such Ordinary Shares shall cease to be Registrable Shares upon the earliest of (A) when they are sold by a Holder, whether pursuant
to an effective registration statement under the Securities Act, pursuant to Rule 144 under the Securities Act or otherwise, (B) when they shall have ceased to be outstanding, and (C) when they may be sold pursuant to Rule 144 under the
Securities Act without the requirement to be in compliance with Rule 144(c)(1) under the Securities Act and without restriction on the basis of volume or manner of sale limitations. 

  
 - 7 - 

 “Securities Act” shall mean the U.S. Securities Act of 1933, as amended,
and the rules and regulations promulgated thereunder. 
 “Von Prondzynski Shares” shall mean the 10,000 Ordinary Shares
owned by Mr. von Prondzynski as of the date hereof and originally subscribed for by Mr. von Prondzynski pursuant to that certain Subscription Agreement, dated as of August 3, 2018, between the Company and Mr. von Prondzynski, at
a price of 7.54 per share (which was equal to the closing bid price of the Company’s Ordinary Shares as reported on the Nasdaq Global Market on August 2, 2018), for aggregate proceeds of $75,400. 

“Walt Shares” shall mean the 45,000 Ordinary Shares owned by Mr. Walt as of the date hereof and originally subscribed
for by Mr. Walt pursuant to that certain Subscription Agreement, dated as of August 3, 2018, between the Company and Mr. Walt, at a price of 7.54 per share (which was equal to the closing bid price of the Company’s Ordinary
Shares as reported on the Nasdaq Global Market on August 2, 2018), for aggregate proceeds of $339,300. 
 Section 2.2
Interpretation. Whenever used herein, the words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation,” and the words “hereof” and
“herein” and similar words shall be construed as references to this Agreement as a whole and not limited to the particular Article, Section or Exhibit in which the reference appears. Unless the context otherwise requires, references
herein: (a) to Articles, Sections and Exhibits mean the Articles and Sections of, and Exhibits attached to, this Agreement; (b) to an agreement, instrument or other document means such agreement, instrument or other document as amended,
supplemented and modified from time to time to the extent permitted by the provisions thereof; and (c) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated
thereunder. The Exhibits attached hereto shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein. The headings of the Articles and Sections are for convenience of reference
only and do not affect the interpretation of any of the provisions hereof. 
 ARTICLE III 

MISCELLANEOUS 

Section 3.1 Term. This Agreement shall terminate on the earliest of (a) upon written notice at any time the Company is not
eligible to file a registration statement on Form S-3 by the Company to the Holders, (b) with respect to any Holder, the date on which such Holder ceases to own any Registrable Shares, or (c) with
respect to any Holder, upon written notice at any time by such Holder to the Company; provided that in the event of any termination pursuant to this clause (c), any such Holder shall not use the Shelf Registration Statement and the prospectus
relating thereto to sell any of the Registrable Shares during any Blackout Period pending at the time of such termination. Section 1.5 and Articles II and III shall survive any termination. 

  
 - 8 - 

 Section 3.2 Notices. All notices, requests and other communications under or by
reason of this Agreement must be in writing and will be deemed to have been duly given (a) when personally delivered, (b) when transmitted (except, if not a Business Day, then the next Business Day) by facsimile or email, or (c) upon
receipt of such notice by the intended Party if sent by any other means. Notices, requests and other communications, in each case to the respective Parties, shall be sent to the applicable address or facsimile number set forth below or on such
Party’s signature page, as applicable (or at such other address or facsimile number as the Party shall furnish the other Parties in accordance with this Section 3.2): 

(a) If to a Holder, then to the address for notices set forth in such Holder’s Questionnaire. 

(b) If to the Company, to: 

Quotient Limited 
 B1, Business
Park, Terre Bonne 
 Route de Crassier 13 

1262 Eysins, Switzerland 
 Attn:
Ernie Larnach 
 Facsimile: + 

Email: 
 with a copy (which shall
not constitute notice) to: 
 Clifford Chance US LLP 

31 West 52nd Street 
 New York,
New York 10019 
 Attn: Per B. Chilstrom 

Facsimile: 
 Email: 

Section 3.3 Successors and Assigns. Neither this Agreement nor any of the rights or obligations hereunder shall be assigned by any
of the Parties without the prior written consent of the Company. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. Any
attempted assignment in violation of this Section 3.3 shall be void. 
 Section 3.4 Governing Law. THIS AGREEMENT AND ALL
CLAIMS, ACTIONS, SUITS OR LEGAL PROCEEDINGS OF ANY KIND (WHETHER AT LAW, IN EQUITY, IN CONTRACT, IN TORT OR OTHERWISE) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS AGREEMENT (INCLUDING THE EXHIBITS HERETO), OR THE NEGOTIATION, EXECUTION OR
PERFORMANCE HEREOF SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD FOR THE CONFLICTS OF LAWS PRINCIPLES THEREOF THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION. 

  
 - 9 - 

 Section 3.5 Counterparts. 

(a) This Agreement may be executed in any number of counterparts, all of which will constitute one and the same instrument. 

(b) Counterparts may be delivered via facsimile, electronic mail (including .pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 (c) No Party hereto shall
raise the use of a facsimile machine or email to deliver a signature or the fact that any signature or agreement was transmitted or communicated through the use of facsimile machine or email as a defense to the formation of a contract, and each such
Party forever waives any such defense. 
 Section 3.6 Entire Agreement. This Agreement, including all Exhibits hereto, supersede
all prior and contemporaneous discussions and agreements, both written and oral, among the Parties with respect to the subject matter hereof and constitute the sole and entire agreement among the Parties to this Agreement with respect to the subject
matter hereof and thereof. 
 Section 3.7 Amendment and Waiver. The provisions of this Agreement, including the provisions of
this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the Company has obtained the written consent of Holders of a majority of outstanding Registrable
Shares; provided, however, that, no consent is necessary from any of the Holders in the event that this Agreement is amended, modified or supplemented for the purpose of curing any ambiguity, defect or inconsistency that does
not adversely affect the rights of any Holders. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or Holders of Registrable Shares and
that does not directly or indirectly affect the rights of other Holders of Registrable Shares may be given by the Holder or Holders of at least a majority of the Registrable Shares affected by such waiver or consent; provided, however,
that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the immediately preceding sentence. Each Holder of Registrable Shares outstanding at the time of any such
amendment, modification, supplement, waiver or consent or thereafter shall be bound by any such amendment, modification, supplement, waiver or consent effected pursuant to this Section 3.7, whether or not any notice, writing or marking
indicating such amendment, modification, supplement, waiver or consent appears on the Registrable Shares or is delivered to such Holder. 

Section 3.8 Invalid Provisions. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any
present or future Law, and if the rights or obligations of any Party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and
enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom and (d) upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties hereto shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 

  
 - 10 - 

 Section 3.9 No Third-Party Beneficiaries. The terms and provisions of this
Agreement are intended solely for the benefit of each Party hereto and their respective successors and permitted assigns, and it is not the intention of the Parties to confer third-party beneficiary rights upon any other Person other than the
Persons indemnified under Section 1.5. 
 [The remainder of this page left intentionally blank.] 

  
 - 11 - 

 IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement by their authorized
representatives as of the date first above written. 
  

			
	QUOTIENT LIMITED
		
	By:	 	/s/ Edward Farrell
		 	Name: Edward Farrell
		 	Title: President

  

			
	CHRISTOPHER J. LINDOP
		
	By:	 	/s/ Christopher J. Lindop
		 	

  

			
	HEINO VON PRONDZYNSKI
		
	By:	 	/s/ Heino von Prondzynski
		 	

  

			
	FRANZ WALT
		
	By:	 	/s/ Franz Walt
		 	

 [Holder Signature Page to Registration Rights Agreement] 

 EXHIBIT A 

PLAN OF DISTRIBUTION 
 We
are registering the ordinary shares previously issued to permit the resale of these ordinary shares by the holders of the ordinary shares from time to time after the date of this prospectus. We have agreed to keep the registration statement of which
this prospectus forms a part current and cause it to remain effective until such time as the ordinary shares covered by the registration statement have been sold or otherwise cease to be registrable securities under the Registration Rights
Agreement, or the date on which the Registration Rights Agreement is terminated in accordance with its terms. We will not receive any of the proceeds from the sale by the selling shareholders of the ordinary shares. We will bear all fees and
expenses incident to our obligation to register the ordinary shares, other than any commissions and transfer taxes of any selling shareholder and the fees, disbursements and expenses of any legal counsel to any selling shareholder. 

The selling shareholders may (subject to receipt by us and/or such selling shareholders of any applicable regulatory consents) sell all or a
portion of the ordinary shares beneficially owned by them and offered hereby from time to time directly or through one or more broker-dealers or agents. If the ordinary shares are sold through broker-dealers, the selling shareholders will be
responsible for commissions. The ordinary shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may
be effected in transactions, which may involve crosses or block transactions: 
  

	 	•	 	 on any national securities exchange or quotation service on which the shares may be listed or quoted at the time
of sale; 

  

	 	•	 	 in the over-the-counter market;

  

	 	•	 	 in transactions otherwise than on these exchanges or systems or in the over-the-counter market; 

  

	 	•	 	 through the writing of options, whether such options are listed on an options exchange or otherwise;

  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

  

	 	•	 	 block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; 

  

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

 

	 	•	 	 an exchange distribution in accordance with the rules of the applicable exchange; 

 

	 	•	 	 privately negotiated transactions; 

  
 Exh. B-1 

	 	•	 	 short sales; 

  

	 	•	 	 sales pursuant to Rule 144 of the Securities Act; 

 

	 	•	 	 broker-dealers may agree with the selling shareholders to sell a specified number of such shares at a stipulated
price per share; 

  

	 	•	 	 a combination of any such methods of sale; and 

 

	 	•	 	 any other method permitted pursuant to applicable law. 

If the selling shareholders effect such transactions by selling ordinary shares to or through broker-dealers or agents, such broker-dealers or
agents may receive commissions in the form of concessions or commissions from the selling shareholders or commissions from purchasers of the ordinary shares for whom they may act as agent or to whom they may sell as principal (which concessions or
commissions as to particular broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the ordinary shares or otherwise, the selling shareholders may enter into hedging
transactions with broker-dealers, which may in tum engage in short sales of the ordinary shares in the course of hedging in positions they assume. The selling shareholders may also sell ordinary shares short and deliver ordinary shares covered by
this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling shareholders may also loan or pledge ordinary shares to broker-dealers that in turn may sell such shares. 

The selling shareholders may pledge or grant a security interest in some or all of the ordinary shares owned by them and, if they default in
the performance of their secured obligations, the pledgees or secured parties may offer and sell the ordinary shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision
of the Securities Act, amending, if necessary, the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may transfer and donate
the ordinary shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

The selling shareholders and any broker-dealer participating in the distribution of the ordinary shares may be deemed to be
“underwriters” within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the
time a particular offering of the ordinary shares is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of ordinary shares being offered and the terms of the offering, including the name or
names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling shareholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. In compliance
with the Financial Industry Regulatory Authority, Inc. (or FINRA) guidelines, the maximum commission or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered
pursuant to this prospectus. 

  
 Exh. B-2 

 Under the securities laws of some states, the ordinary shares may be sold in such states
only through registered or licensed brokers or dealers. In addition, in some states the ordinary shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is
available and is complied with. 
 There can be no assurance that any selling shareholder will sell any or all of the ordinary shares
registered pursuant to the registration statement of which this prospectus forms a part. 
 The selling shareholders and any other person
participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and
sales of any of the ordinary shares by the selling shareholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the ordinary shares to engage in market-making activities
with respect to the ordinary shares. Further, regulatory consents may be required in Jersey, Channel Islands in connection with certain types of offers of ordinary shares by selling shareholders, including offers to more than 50 persons other than
on any national securities exchange or quotation service on which the securities are listed or quoted at the time of sale. All of the foregoing may affect the marketability of the ordinary shares and the ability of any person or entity to engage in
market-making activities with respect to the ordinary shares. 
 In connection with our November 2019 underwritten public offering of
ordinary shares, the selling shareholders in this offering entered into certain lock-up agreements with the representatives of the underwriters for that underwritten public offering. Under the terms of these lock-up agreements, subject to certain exceptions, the selling shareholders will be restricted from selling ordinary shares under this prospectus for a 90-day period ending
February 4, 2020, unless these restrictions are earlier waived by the representatives in their sole discretion. 
 We will pay all
expenses of the registration of the ordinary shares pursuant to the Registration Rights Agreement, other than any commissions and transfer taxes of any selling shareholder and the fees, disbursements and expenses of any legal counsel to any selling
shareholder. The total fees are estimated to be $44,618 in total, including, without limitation, SEC filing fees and expenses of compliance with state securities or “Blue Sky” laws. We may be indemnified by the selling shareholders against
civil liabilities, including liabilities under the Securities Act, that may arise from any written information furnished to us by the selling shareholder specifically for use in this prospectus, in accordance with the Registration Rights Agreement,
or we may be entitled to contribution. 
 Once sold under the registration statement, of which this prospectus forms a part, the ordinary
shares will be freely tradable in the hands of persons other than our affiliates. 

  
 Exh. B-3 

 EXHIBIT B 

QUOTIENT LIMITED 
 FORM OF
SELLING SHAREHOLDER QUESTIONNAIRE 
 The undersigned is the beneficial owner of Quotient Limited (the “Company”)
ordinary shares, no par value per share (the “Ordinary Shares”). Pursuant to and in accordance with the terms of the Registration Rights Agreement, dated as of [    ] (the “Registration Rights
Agreement”), among the Company and the Holders named therein, including the undersigned, the Company intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement for the registration
and resale of certain Ordinary Shares held by the undersigned, as provided in the Registration Rights Agreement. This registration statement is referred to as the “Shelf Registration Statement.” The Ordinary Shares being registered
for resale are referred to as the “Registrable Shares.” All capitalized terms not otherwise defined herein have the meanings ascribed thereto in the Registration Rights Agreement. 

Generally, “beneficial ownership” means the sole or shared power to vote or dispose of the securities in question. This concept is
very important to the SEC and the following definition explains the concept further. By virtue of the ownership or co-ownership of a security, directly or indirectly, through any contract, arrangement,
understanding, relationship or any other means, to have or share: (i) voting power, which includes the power to vote, or to direct the voting of, such security; and/or (ii) investment power, which includes the power to dispose, or to
direct the disposition of, such security. 
 You are understood to be the beneficial owner of a security if, directly or indirectly, you
create or use a trust, proxy, power of attorney, pooling arrangement, combination or any other contract or device with the purpose or effect of transmitting or maintaining ownership of a security. 

You are also understood to be the beneficial owner of a security if you have the right to acquire the beneficial ownership of such security,
at any time, within a period of 60 days, including, without limitation, any right to acquire it: (i) through the exercise of any option, warrant, certificate for the purchase of shares or rights, (ii) through the conversion of a security,
(iii) pursuant to the power to revoke a trust, discretionary account or similar arrangement, or (iv) pursuant to the automatic termination of a trust, discretionary account or similar arrangement. 

All shares beneficially owned by you, regardless of the manner of such ownership, should be counted together when calculating the total amount
of shares you beneficially own. Please note that more than one person may beneficially own the same security. 
 The scope of the foregoing
definition is broad, and even if you do not have voting rights or the right to invest with regards to the shares beneficially owned by members of your family or people living in your household, you should include those shares in your statement and,
if applicable, state that you do not beneficially own them. 

  
 Exh. B-4 

 In order to sell or otherwise dispose of any Registrable Shares pursuant to the Shelf
Registration Statement, a beneficial owner of Registrable Shares generally will be required to be named as a selling shareholder in the related prospectus, deliver a prospectus to purchasers of Registrable Shares and be bound by those provisions of
the Registration Rights Agreement (including certain indemnification provisions as described below). The undersigned beneficial owner (the “Shareholder”) desires to include the Registrable Shares beneficially owned by it and listed
below in Item 3 of this Questionnaire in the Shelf Registration Statement and is properly completing, signing and delivering this Questionnaire to the Company in order to include such Registrable Shares. 

Certain legal consequences arise from being named as selling shareholders in the Shelf Registration Statement and the related prospectus.
Investors and beneficial owners of Registrable Shares are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling shareholder in the Shelf Registration Statement and the related
prospectus or, for those choosing to sell under Rule 144 (“Rule 144”) of the Securities Act of 1933, as amended (the “1933 Act”), the requirements of Rule 144. 

The undersigned, by signing and returning this Questionnaire, understands that it will be bound by the terms and conditions of this
Questionnaire and the Registration Rights Agreement. 
 Pursuant to the Registration Rights Agreement, and subject to certain limitations
described therein, the undersigned has agreed to severally and not jointly indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 1.5 of the Registration Rights Agreement, the Company, each of
its directors, officers, shareholders, employees, accountants, attorneys and agents and each Person, if any, who controls the Company within the meaning of the 1933 Act or the U.S. Securities Exchange Act of 1934, as amended (the “1934
Act”), against certain Losses to which any of them have become subject, as incurred, arising out of, caused by, resulting from or relating to any untrue statement (or alleged untrue statement) of material fact contained in the Shelf
Registration Statement or any omission (or alleged omission) of a material fact required to be stated therein or necessary to make the statements therein not misleading, solely to the extent, but only to the extent, that such untrue statement or
omission is made in the Shelf Registration Statement in reliance upon and in conformity with written information regarding such Shareholder furnished to the Company by or on behalf of such Shareholder expressly for inclusion in the Shelf
Registration Statement. 
 The undersigned hereby provides the following information to the Company and represents and warrants that such
information is accurate and complete: 
 QUESTIONNAIRE 
  

	1.	 (a)   Full legal name of Shareholder (i.e., beneficial owner) of the Registrable Shares listed in
Item 3 below: 

  

			
		 	 

			
	  
 (b)
	 	  
 Full legal name of the record holder, including the name of the
broker dealer, if applicable, through which Registrable Shares listed in Item 3 below are held:

  

			
		 	 

  
 Exh. B-5 

	 	(c)	 Full legal name of DTC Participant (if applicable and if not the same as (b) above) through which
Registrable Shares listed in Item 3 below are held: 

			
	 	 	 

  

			
	2.       Address for notices to Shareholder:	 	 

			
		
	Telephone:	 	 

			
		
	Fax:	 	 

			
		
	Email address:	 	 

			
		
	Contact Person:	 	 

  

	3.	 Beneficial ownership of Registrable Shares 

Please state the name of each person who has voting or investment power over the Registrable Shares indicated below. Voting power includes the
power to vote, or to direct the voting of, the Registrable Shares held by the undersigned. Investment power includes the power to dispose, or to direct the disposition of, the Registrable Shares held by the undersigned directly or indirectly,
through any contract, arrangement, understanding or relationship. Please provide the requested information for each such person: 
 Number of
Registrable Shares beneficially owned and to be included in the Shelf Registration Statement: 
  

			
		
	Sole voting power:	 	 

			
		
	Shared voting power:	 	 

			
		
	Sole investment power:	 	 

			
		
	Shared investment power:	 	 

  

	4.	 Beneficial ownership of Company securities, other than Registrable Shares listed in Item 3 above, owned by
the Shareholder: 

 Type and amount of other securities beneficially owned by the Shareholder: 

 

			
	 

  

	5.	 Relationship with the Company: 

 

			
	 

  
 Exh. B-6 

	 	(a)	 Has the Shareholder or any of its affiliates, officers, directors or principal equity holders (owners of 5% or
more of the equity securities of the Shareholder) held any position or office or has the Shareholder had any other material relationship with the Company (or its predecessors or affiliates) within the past three years? 

☐ Yes. 
 ☐ No. 

 

	 	(b)	 If “Yes,” please state the nature and duration of the relationship with the Company:

  

			
	 
	
	 

  

	6. (a)	 Broker-Dealer Status 

Is the Shareholder a broker-dealer registered pursuant to Section 15 of the 1934 Act? 

☐ Yes. 
 ☐ No. 

Note that we will be required to identify any registered broker-dealer as an underwriter in the Shelf Registration Statement and related
prospectus. 
 If the Shareholder is a registered broker-dealer, please indicate whether the Shareholder purchased its Registrable Shares
for investment or acquired them as transaction-based compensation for investment banking or similar services. 
  

			
	 
	
	 

 If
the Shareholder is a registered broker-dealer and received its Registrable Shares other than as transaction-based compensation, the Company is required to identify the Shareholder as an underwriter in the Shelf Registration Statement and related
prospectus. 
  

	 	(b)	 Affiliation with Broker-Dealers: 

Is the Shareholder an affiliate of a registered broker-dealer? For purposes of this Item 6(b), an “affiliate” means a person or
entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the person or entity specified. 

☐ Yes. 
 ☐ No. 

If “Yes,” please answer the remaining questions in this section. 

  
 Exh. B-7 

	 	(i)	 Please describe the affiliation between the Shareholder and any registered broker-dealers:

  

			
	 
	
	 

  

	 	(ii)	 If the Registrable Shares were purchased by the Shareholder other than in the ordinary course of business,
please describe the circumstances: 

  

			
	 
	
	 

  

	 	(iii)	 If the Shareholder, at the time of its purchase of Registrable Shares, has had any agreements or
understandings, directly or indirectly, with any person to distribute the Registrable Shares, please describe such agreements or understandings: 

  

			
	 
	
	 

Note that if the Shareholder is an affiliate of a broker-dealer and did not purchase its Registrable Shares in the ordinary course of
business or at the time of the purchase had any agreements or understandings, directly or indirectly, to distribute the securities, we must identify the Shareholder as an underwriter in the Shelf Registration Statement and related prospectus.

  

	7.	 Nature of Beneficial Holding. The purpose of this question is to identify the ultimate natural person(s) or
publicly held entity that exercises sole or shared voting or dispositive power over the Registrable Shares. 

  

	 	(a)	 Is the Shareholder a natural person? 

☐ Yes. 
 ☐ No. 

If the Shareholder answered “Yes” to Item 7(a), please proceed to Item 8 below. 

 

	 	(b)	 Is the Shareholder required to file, or is it a wholly owned subsidiary of a company that is required to file,
periodic and other reports (for example, Forms 10-K, 10-Q, 8-K) with the SEC pursuant to Section 13(a) or 15(d) of the 1934
Act? 

 ☐ Yes. 

☐ No. 

  
 Exh. B-8 

	 	(c)	 State whether the Shareholder is an investment company, or a subsidiary of an investment company, registered
under the U.S. Investment Company Act of 1940, as amended: 

 ☐ Yes. 

☐ No. 
 If a subsidiary,
please identify the publicly held parent entity: 
  

			
	 
	
	 

  

	 	(d)	 If the Shareholder answered “No” to questions (a), (b) and (c) above, please identify the
controlling person(s) of the Shareholder (the “Controlling Entity”). If the Controlling Entity is not a natural person or a publicly held entity, please identify each controlling person(s) of such Controlling Entity. This process
should be repeated until the Shareholder reaches natural persons or a publicly held entity that exercise sole or shared voting or dispositive power over the Registrable Shares: 

 

			
	
	 

 *** PLEASE NOTE
THAT THE SEC REQUIRES THAT THESE NATURAL PERSONS BE NAMED IN THE PROSPECTUS *** 
 If you need more space for this response, please
attach additional sheets of paper. Please be sure to indicate your name and the number of the item being responded to on each such additional sheet of paper, and to sign each such additional sheet of paper before attaching it to this Questionnaire.
Please note that you may be asked to answer additional questions depending on your responses to the above questions. 
  

	8.	 Plan of Distribution: 

The Shelf Registration Statement must disclose the manner in which the Shareholder’s Registrable Shares will be sold. Exhibit A of the
Registration Rights Agreement sets forth the text of the Plan of Distribution substantially in the form in which it will appear in the Shelf Registration Statement. The Plan of Distribution describes the ways in which the Shareholder’s
Registrable Shares may be sold. Please confirm the information set forth in Exhibit A to the Registration Rights Agreement. 
 State any
exceptions here: 
  

			
	 
	
	 
	
	 

  
 Exh. B-9 

	Note:	 In no event may such method(s) of distribution take the form of an underwritten offering of the Registrable
Shares without the prior written consent of the Company. 

 The Company hereby advises each Shareholder of Compliance
and Disclosure Interpretation 239.10 published by the Division of Corporation Finance of the SEC, as set forth below, regarding short selling: 

“An issuer filed a Form S-3 registration statement for a secondary offering of common stock which
is not yet effective. One of the selling shareholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could
not be made before the registration statement becomes effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were
effectively sold prior to the effective date.” 
 By returning this Questionnaire, the Shareholder will be deemed to be aware of the
foregoing interpretation. 
 The undersigned acknowledges that it understands its obligation to comply with the provisions of the 1934 Act
and the rules thereunder relating to stock manipulation, particularly Regulation M thereunder (or any successor rules or regulations), in connection with any offering of Registrable Shares pursuant to the Shelf Registration Statement. The
undersigned agrees that neither it nor any person acting on its behalf will engage in any transaction in violation of such provisions. 

The Shareholder hereby acknowledges its obligations under the Registration Rights Agreement to indemnify and hold harmless certain persons set
forth therein. 
 In accordance with the undersigned’s obligation under the Registration Rights Agreement to provide such information
as may be required by law for inclusion in the Shelf Registration Statement, the undersigned agrees to provide any additional information the Company may reasonably request and to promptly notify the Company of any inaccuracies or changes in the
information provided that may occur at any time while the Shelf Registration Statement remains effective. 
 By signing this
Questionnaire, the undersigned consents to the disclosure of the information contained herein in its answers to the above questions and the inclusion of such information in the Shelf Registration Statement and the related prospectus. The undersigned
understands that such information will be relied upon by the Company without independent investigation or inquiry in connection with the preparation or amendment of the Shelf Registration Statement and the related prospectus. 

Once this Questionnaire is executed by the Shareholder and received by the Company the terms of this Questionnaire and the representations and
warranties contained herein shall be binding on, shall inure to the benefit of, and shall be enforceable by the respective successors, heirs, personal representatives and assigns of the Company and the Shareholder with respect to the Registrable
Shares beneficially owned by such Shareholder and listed in Item 3 above. This Questionnaire shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the conflicts-of-laws provisions thereof. 

  
 Exh. B-10 

 IN WITNESS WHEREOF, the undersigned, by authority duly given, has caused this Questionnaire
to be executed and delivered either in person or by its authorized agent. 
 Dated: [    ] 

 

			
	Beneficial Owner:
		
	By:	 	 
		 	Name:
		 	Title:

 Please return the completed and executed questionnaire to: 

QUOTIENT LIMITED 
 B1, Business
Park, Terre Bonne 
 Route de Crassier 13 

1262 Eysins, Switzerland 

Facsimile: +[    ] 

Attention: Ernie Larnach 
 With
an electronic mail copy to: 
 [    ] 

  
 Exh. B-11EX-10.1

 Exhibit 10.1 
  

			
	

	  	 Franz Walt

 Private & Confidential 

Roland Boyd 
 5 Trench Knowe 

Edinburgh 
 EH10 7HL 

December 10, 2019 
 Dear Roland, 

Transition Agreement 
 We would like to thank you for your
service to Quotient Limited (the “Company”) since joining. This letter, when fully executed, will constitute the Transition Agreement (“Agreement”) between you and the Company concerning the terms of your upcoming retirement from
employment with the Company. 
 1. Retirement. Unless terminated sooner, your employment with the Company and its subsidiaries and
other controlled affiliates will end upon your retirement on December 31, 2019 (the “Retirement Date”). You hereby resign from all directorships, officerships and other positions with the Company and its controlled affiliates as of
and with effect from the Retirement Date. You agree to sign all appropriate documentation, if any, prepared by the Company in connection with those resignations. The Company and you agree that this Agreement satisfies any notice requirement that
otherwise may apply to your retirement and termination of employment under your Employment Agreement, dated as of August 14, 2012, as amended, between the Company and you (your “Employment Agreement”) and any other agreement between
you and the Company or any of its affiliates. 
 2. Pre-Retirement Services. Between now and
the Retirement Date you will continue to provide such services as may be requested by the Company’s Chief Executive Officer and Chief Financial Officer. As of the date of this Agreement, the Company anticipates that you will continue in your
role as Group Chief Financial Controller & Treasurer and ensure that an appropriate transition of your responsibilities is undertaken with appropriate team members prior to the Retirement Date, ensuring continuity of your current activities
post retirement. 
 Alba Bioscience Limited, Registered in Scotland No. SC310584 

Allan-Robb Campus, 5 James Hamilton Way, Milton Bridge, Penicuik EH26 0BF 

T +44 (0) 131 357 3333, quotientbd.com 

 

 
  

 3. Compensation. 

 

	 	a)	 Until your retirement or earlier separation from the Company, you will continue to receive the same base salary
as at present; you will continue to have the same bonus opportunity as at present; and you will be entitled to the same non-cash benefits as at present. 

 

	 	b)	 Provided that you remain an employee and continue to provide services to the Company through the Retirement
Date in accordance with Section 2 and subject to the other requirements of this Agreement, we would like to recognise your service by providing you with (i) a single cash payment (the “Retirement Payment”) of £213,000,
equal to twelve months base salary plus (ii) a pro rated portion of your FY20 bonus. The Company’s obligation to make the Retirement Payment is expressly conditioned upon you agreeing to the terms of this document and providing the
services outlined in Section 2. The Company will make the Retirement Payment in the payroll period following the Retirement Date. 

4. Benefits. Provided that you (i) remain an employee and continue to provide services to the Company through the Retirement Date in
accordance with Section 2, and (ii) comply with the other requirements of this Agreement, the Company will provide you with the following benefits (the “Benefits”): 

 

	 	a)	 All unvested options to acquire ordinary shares of the Company (“Options”) which you hold that are
scheduled to vest within twelve months following the Retirement Date will remain outstanding and vest and become exercisable on their regularly scheduled vesting dates after the Retirement Date; all other unvested Options which you hold will be
forfeited on the Retirement Date; all outstanding and vested Options which you hold will remain exercisable until the twelve month anniversary of the Retirement Date at which time they will expire. 

 

	 	b)	 All unvested RSUs which you hold that are scheduled to vest within twelve months following the Retirement Date
will remain outstanding and vest on their regularly scheduled vesting dates after the Retirement Date; all other unvested RSUs which you hold will be forfeited on the Retirement Date. 

5. Company Property. You agree to return all Company property in your possession within 14 days following the Retirement Date. Company
property includes work product, electronic devices and other physical property of the Company. This includes equipment, supplies, keys, security items, credit cards, passwords, electronic devices, laptop computers and mobile phones. You must also
return all originals and any copies of Company records. This includes any disks, files, notebooks, etc. that you have personally generated or maintained with respect to the Company’s business, as well as any Company records in your possession.
In addition, you and the Company agree to cooperate in good faith in identifying, providing you access to and appropriately segregating property belonging to you and maintained on Company premises on the Retirement Date. 

  

			
	 Alba Bioscience Limited, Registered in Scotland No. SC310584

Allan-Robb Campus, 5 James Hamilton Way, Milton Bridge, Penicuik EH26 0BF

T +44 (0) 131 357 3333, quotientbd.com
	  	Page 2/4

 

 
  

 6. Continued Assistance. After the Retirement Date we request that you will be available
to provide consultancy services to the Company to support any special projects that may arise. The Company will compensate you for all time spent providing such assistance after the Retirement Date at the rate of £1300 per day plus your
reasonable out-of-pocket expenses. This clause will expire 12 months after the Retirement Date. 

7. Covenants. Before and after the Retirement Date, you will remain subject to and continue to comply with all the restrictive and other
covenants contained in your Employment Agreement including in respect of confidentiality, noncompetition and nonsolicitation. 
 8.
Confidentiality. You acknowledge that the Company’s Confidential Information (as defined in your Employment Agreement) is proprietary and that you may never disclose any such information to any person or entity at any time,
including after the Retirement Date. You agree this paragraph is a material provision of this Agreement and that in the event of breach, you will be liable for the return of the value of all consideration received as well as any other damages
sustained by the Company. 
 9. Forfeiture. In the event that you breach any of your obligations to the Company under this Agreement,
your Employment Agreement or as otherwise imposed by law, the Company shall be entitled to stop payment of any benefit due under this Agreement and shall be entitled to recover any benefit paid after the Retirement Date under this Agreement and to
obtain all other relief provided by law or equity, including, but not limited to, injunctive relief. 
 10. Severability. If any
portion, provision or part of this Agreement is held, determined or adjudicated to be invalid, unenforceable or void for any reason whatsoever, each such portion, provision or part shall be severed from the remaining portions, provisions or parts of
this Agreement and shall not affect the validity or enforceability of such remaining portions, provisions or parts. 
 11. Entire
Agreement. This Agreement between you and the Company is in consideration of the mutual promises described above. This Agreement constitutes the entire agreement between you and the Company with respect to your retirement and related
separation from employment. There are no other agreements, written or oral, expressed or implied, between the parties hereto, concerning the subject matter hereof, except the agreements set forth in this Agreement. 

12. Withholding. All payments made to you pursuant to this Agreement are subject to all applicable Tax, National Insurance and
other withholdings required by law. You acknowledge and agree that all taxes imposed on you by reason of the payments and benefits hereunder are your sole responsibility and the Company is in no way indemnifying you or holding you harmless in
respect of any such taxes. The Company shall not be liable to you (or any other individual claiming a benefit through you) for any tax, interest, or penalties you may owe as a result of compensation paid under this Agreement, and the Company shall
have no obligation to indemnify or otherwise protect you from the obligation to pay any taxes. 

  

			
	 Alba Bioscience Limited, Registered in Scotland No. SC310584

Allan-Robb Campus, 5 James Hamilton Way, Milton Bridge, Penicuik EH26 0BF

T +44 (0) 131 357 3333, quotientbd.com
	  	Page 3/4

 

 
  

 We would appreciate if you could sign both copies of this agreement, returning one copy to Human Resources
and retaining the other for your records. 
 We wish you every success in your retirement and thank you again for all your support over the years. 

Yours sincerely, 
  

							
	By:	 	/s/ Franz Walt	 		 	/s/ Chris Lindop
				
	Name:	 	Franz Walt	 		 	Chris Lindop
				
	Title:	 	Chief Executive Officer	 		 	Chief Financial Officer

 By signing below, I acknowledge that I have been given the opportunity to review this Retirement & Transition
Agreement carefully; that I have read this Agreement and understand the terms of the Agreement; and that I voluntarily agree to them. 
  

			
	ACCEPTED AND AGREED TO:
		
	By:	 	/s/ Roland Boyd
		
	Name:	 	Roland Boyd
		
	Date:	 	10th December, 2019

  

			
	 Alba Bioscience Limited, Registered in Scotland No. SC310584

Allan-Robb Campus, 5 James Hamilton Way, Milton Bridge, Penicuik EH26 0BF

T +44 (0) 131 357 3333, quotientbd.com
	  	Page 4/4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]